FDA’s Landmark Guidance on Decentralized Clinical Trials (DCTs) Signals a New Era of Patient-Centered Research

In this paper, published in MedCity News, Science 37 Chief Medical Officer Dr. Jonathan Cotliar explores the FDA Draft Guidance on decentralized clinical trials (DCTs). With the FDA’s acceptance and encouragement of decentralized trials, we can expect to see a continued shift towards remote trial conduct, virtual sites, and the use of innovative digital technologies.